Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

NCT05036798 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

Interventions

DRUG: Tislelizumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital